MX9707569A - Un metodo para el tratamiento de la degeneracion macular. - Google Patents

Un metodo para el tratamiento de la degeneracion macular.

Info

Publication number
MX9707569A
MX9707569A MX9707569A MX9707569A MX9707569A MX 9707569 A MX9707569 A MX 9707569A MX 9707569 A MX9707569 A MX 9707569A MX 9707569 A MX9707569 A MX 9707569A MX 9707569 A MX9707569 A MX 9707569A
Authority
MX
Mexico
Prior art keywords
macular degeneration
treatment
exudative
oxidant
onset
Prior art date
Application number
MX9707569A
Other languages
English (en)
Inventor
John E Repine
Original Assignee
John E Repine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John E Repine filed Critical John E Repine
Publication of MX9707569A publication Critical patent/MX9707569A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Finger-Pressure Massage (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

La degeneracion macular es una enfermedad del ojo relacionada con la edad para la cual no hay hasta la fecha un tratamiento conocido que haya mostrado ser efectivo en el tratamiento prevencion del ataque o progresion de la enfermedad. El tratamiento actual de la degeneracion macular no-exudativa (forma seca) está limitado a un diagnostico temprano y a un tratamiento complementario cuidadoso, mientras que el tratamiento sintomático de la degeneracion macular exudativa (forma humeda) incluye terapia de fotocoagulacion por láser, cirugía, radiacion de dosificacion baja (teleterapia) y terapias anti-oxidantes o anti-inflamatorias. La presente invencion está relacionada con un nuevo método para el tratamiento o prevencion del ataque o progresion de la degeneracion macular, el comprende la administracion periodica de una agente mejorador del glutation (GSH) solo o en conjuncion con al menos una terapia anti-oxidante o anti-inflamatoria, y posiblemente, en adicion, a uno o más de los tratamientos sintomáticos mencionados anteriormente.
MX9707569A 1995-04-06 1996-03-29 Un metodo para el tratamiento de la degeneracion macular. MX9707569A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/418,645 US5596011A (en) 1995-04-06 1995-04-06 Method for the treatment of macular degeneration
PCT/US1996/003642 WO1996031212A1 (en) 1995-04-06 1996-03-29 A method for the treatment of macular degeneration

Publications (1)

Publication Number Publication Date
MX9707569A true MX9707569A (es) 1997-12-31

Family

ID=23658985

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9707569A MX9707569A (es) 1995-04-06 1996-03-29 Un metodo para el tratamiento de la degeneracion macular.

Country Status (11)

Country Link
US (1) US5596011A (es)
EP (1) EP0819003A4 (es)
JP (1) JPH11503152A (es)
CN (1) CN1106842C (es)
AU (1) AU691108B2 (es)
CA (1) CA2216281A1 (es)
IL (1) IL117793A0 (es)
MX (1) MX9707569A (es)
TW (1) TW426520B (es)
WO (1) WO1996031212A1 (es)
ZA (1) ZA962692B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2136557B1 (es) * 1997-08-22 2000-07-01 Martinez Parra Aurelio Juan Producto para tratamiento de la queratitis seca.
US8198334B2 (en) * 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US6251868B1 (en) * 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
US6379664B1 (en) 1998-09-29 2002-04-30 Board Of Regents University Of Nebraska-Lincoln Composition and method for the prevention and treatment of oxidative damage in ocular tissues
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
WO2000072698A1 (en) 1999-05-27 2000-12-07 The Iams Company Process and product for enhancing immune response in companion animal using a combination of antioxidants
AU7330200A (en) * 1999-08-09 2001-05-10 Webb-Waring Institute For Biomedical Research A method for the treatment of ocular oxidative stress
US6582721B1 (en) * 1999-09-17 2003-06-24 Alcon, Inc. Stable carotene-xanthophyll beadlet compositions and methods of use
US6573299B1 (en) 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
US6875165B2 (en) * 2001-02-22 2005-04-05 Retinalabs, Inc. Method of radiation delivery to the eye
US7226766B2 (en) 2001-06-12 2007-06-05 University Of Iowa Research Foundation S-methylcysteine, S-ethylcysteine, and related S-alkylthiols as antagonists to the effects of S-nitrosothiols and nitric oxide
JP2005520787A (ja) * 2001-09-14 2005-07-14 エヌ．ヴイ．ヌトゥリシア 細胞内に存在するグルタチオンを増加させる方法
JP2005521707A (ja) * 2002-03-28 2005-07-21 オキシス インターナショナル， インコーポレイテッド 神経保護方法、組成物、およびそのスクリーニング法
US8557855B2 (en) * 2002-07-03 2013-10-15 Allergan, Inc. Methods of using ryanodine antagonists in treating neural injury
US7776907B2 (en) 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
EP1447064B1 (en) * 2003-02-12 2010-06-02 Coherent GmbH Kit-of-parts for surgically ablating eye tissue
US20040180090A1 (en) * 2003-03-12 2004-09-16 Demarco Peter Treatment of macular degeneration
JP4694773B2 (ja) * 2003-06-06 2011-06-08 ロート製薬株式会社 粘膜適用液状組成物
US7803103B2 (en) * 2005-02-11 2010-09-28 Neovista Inc. Methods and apparatus for intraocular brachytherapy
US7563222B2 (en) * 2004-02-12 2009-07-21 Neovista, Inc. Methods and apparatus for intraocular brachytherapy
US7744520B2 (en) * 2004-02-12 2010-06-29 Neovista, Inc. Method and apparatus for intraocular brachytherapy
US20050249820A1 (en) * 2004-05-04 2005-11-10 Akorn, Inc. Nutritional supplement for the treatment and prevention of macular degeneration
JP4756837B2 (ja) * 2004-06-03 2011-08-24 ロート製薬株式会社 プラノプロフェン含有組成物
WO2005120544A1 (en) * 2004-06-08 2005-12-22 Paola Ammannati Enzymatic treatment of retinitis pigmentosa and relevant pharmaceutical composition therefor in form of a kit
PL1768657T3 (pl) 2004-06-23 2009-01-30 Revision Therapeutics Inc Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
KR20070091283A (ko) * 2004-11-04 2007-09-10 시리온 테라퓨틱스, 인크. 레티놀-레티놀 결합단백질(ｒｂｐ)-트랜스타이레틴(ｔｔｒ) 복합체 형성의조절 인자
BRPI0520207A2 (pt) * 2004-12-08 2012-09-25 Revision Therapeutics Inc uso de uma quantidade eficaz de um primeiro composto, e, medicamento sistemicamente formulado
US8088773B2 (en) * 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
CN101437575B (zh) * 2006-02-01 2015-04-08 皇家飞利浦电子股份有限公司 改良的放射治疗规划方案
US7282225B1 (en) 2006-09-27 2007-10-16 Occular Technologies, Inc. Composition and methods for improving retinal health
US9084803B2 (en) * 2007-06-29 2015-07-21 Board Of Trustees Of Northern Illinois University Therapeutic uses of glutathione mimics
ITMI20080003A1 (it) * 2008-01-02 2009-07-03 Alfredo Pulpito Composizioni per uso oftalmico
BRPI0913380A2 (pt) 2008-06-04 2015-11-24 Neovista Inc sistema portátil de liberação de radiação para o avanço de um fio de fonte de radiação
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
JP5518608B2 (ja) * 2010-07-09 2014-06-11 ロート製薬株式会社 粘膜適用液状組成物
WO2012135432A2 (en) * 2011-03-29 2012-10-04 Kemin Industries, Inc. Dyes for membranes and biological structures
CN102540500A (zh) * 2012-03-01 2012-07-04 吕伟东 Uvpc色觉矫正眼镜片及制作工艺
AU2013274582A1 (en) 2012-06-11 2015-01-22 Macuclear, Inc. Therapeutic formulation and methods of treatment
KR101423631B1 (ko) * 2012-08-17 2014-07-25 주식회사파마킹 에스-알릴엘-시스테인을 유효성분으로 포함하는 안질환 예방 또는 치료용 조성물 및 이를 포함하는 의약제제
KR102620997B1 (ko) * 2022-11-10 2024-01-04 주식회사 아이두젠 노각나무 추출물을 유효성분으로 포함하는 시력 보호용 또는 망막 질환의 개선 및 예방용 조성물
WO2025250929A1 (en) * 2024-05-31 2025-12-04 Apellis Pharmaceuticals, Inc. Systems and methods for virtual reality, augmented reality, and/or mixed reality based visual function testing based on optokinetic reflex

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8512163D0 (en) * 1985-05-14 1985-06-19 Fujisawa Pharmaceutical Co Oxothiazolidine compound
US5156852A (en) * 1989-04-20 1992-10-20 La Haye Laboratories, Inc. Composition and method for combating macular degeneration
US5310764A (en) * 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
US5208249A (en) * 1992-08-20 1993-05-04 Clintec Nutrition Co. Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration

Also Published As

Publication number Publication date
IL117793A0 (en) 1996-08-04
EP0819003A1 (en) 1998-01-21
CA2216281A1 (en) 1996-10-10
CN1183720A (zh) 1998-06-03
AU5255296A (en) 1996-10-23
WO1996031212A1 (en) 1996-10-10
CN1106842C (zh) 2003-04-30
EP0819003A4 (en) 1999-03-17
JPH11503152A (ja) 1999-03-23
AU691108B2 (en) 1998-05-07
ZA962692B (en) 1996-10-09
US5596011A (en) 1997-01-21
TW426520B (en) 2001-03-21

Similar Documents

Publication Publication Date Title
MX9707569A (es) Un metodo para el tratamiento de la degeneracion macular.
TWI255713B (en) Method for treating meibomian gland disease
Arndt et al. Treatment of pityriasis rosea with UV radiation
WO2002064163A3 (en) Reduction or prevention of pdt related inflammation
MX9302038A (es) Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s.
DE3750836D1 (de) Zwei-stufen-verfahren zur heilung schmerzenfreier wunden, sowie wässriges medium und topische salbe zur verwendung dazu.
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
PL310474A1 (en) Application of rilusole in treating neuro-aids diseases
ATE249819T1 (de) Präparate zur äusserlichen anwendung zur behandlung von dermatosen
IL138290A0 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
CA2282682A1 (en) Tazarotene and corticosteroid treatment for psoriasis
Eberl et al. Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study
GR3032224T3 (en) Therapeutic agent for threatened abortion.
AU4220389A (en) Method for treating and preventing loss of bone mass
Giele et al. Early use of pressure masks to avoid facial contracture during the pregrafting phase
Baehni Supportive care of the periodontal patient
Del Regato Roentgen therapy of carcinoma of the skin of the eyelids
BR9916963A (pt) Bupropiona para tratamento de doenças virais
PT654267E (pt) Carcinoestaticos para terapia hormonal contendo dienogest como componente eficaz
Dellon et al. Perifolliculitis capitis: surgical treatment for the severe case
Naik et al. 8-Methoxypsoralen-lnduced Nail Pigmentation.
Schrems et al. The effect of topically applied prostaglandin inhibitors on the laser-induced disruption of the blood aqueous barrier
DE69528068D1 (de) Conagenine zur prävention und behandlung von diarrhöe
Key Sulfonamides in the treatment of chronic osteomyelitis
WO1998025594A3 (en) Lamotrigine in the treatment and prophylaxis of migraine